Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Cell Biol Int ; 44(3): 821-829, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31814213

RESUMEN

Mitochondrial fission process 1 (MTFP1) is a novel nuclear-encoded protein that promotes mitochondrial fission. Increasing lines of evidence indicate that increased mitochondrial fission is involved in carcinogenesis and tumor progression. However, the expression and biological effects of MTFP1 in cancer development is still unclear, especially in oral squamous cell carcinoma (OSCC). In this study, we first evaluated the expression of MTFP1 in 12-paired OSCC tumor and peritumor tissues. We then explored the effects of MTFP1 knockdown or overexpression on cell growth by cell proliferation, colony formation, cell cycle, and cell apoptosis assays. Furthermore, the mechanisms by which MTFP1 promoted OSCC cell growth were explored. Our results showed that MTFP1 is frequently overexpressed in OSCC tissues. Functional experiments revealed that MTFP1 promoted the growth of OSCC cells by inducing the progression of cell cycle and suppressing cell apoptosis. Mechanistically, MTFP1 overexpression-mediated mitochondrial fragmentation and subsequent ROS production was found to be involved in the promotion of OSCC cell growth. Collectively, our study demonstrates that MTFP1 plays a critical oncogenic role in OSCC carcinogenesis, which may serve as a potential therapeutic target in the treatment of this malignance.


Asunto(s)
Carcinoma de Células Escamosas/metabolismo , Carcinoma de Células Escamosas/patología , Proteínas Mitocondriales/metabolismo , Neoplasias de la Boca/metabolismo , Neoplasias de la Boca/patología , Especies Reactivas de Oxígeno/metabolismo , Apoptosis , Carcinogénesis/genética , Carcinogénesis/metabolismo , Ciclo Celular , Línea Celular Tumoral , Proliferación Celular , Regulación Neoplásica de la Expresión Génica , Humanos , Proteínas Mitocondriales/genética
2.
J Oral Maxillofac Surg ; 77(1): 184-194, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30218654

RESUMEN

PURPOSE: To assess the possible benefits of elective neck dissection (END) in patients with squamous cell carcinoma (SCC) of the oral cavity and clinically N0 neck. MATERIALS AND METHODS: Medline, Embase, the China National Knowledge Infrastructure, and the Wan Fang Database were systematically searched. A meta-analysis was performed to evaluate the possible benefits of END to such patients. RESULTS: Six prospective studies involving 865 patients fulfilled the inclusion criteria. Meta-analysis of all included studies showed that END substantially lowered the risk of regional recurrences (risk ratio [RR] = 0.27; 95% confidence interval [CI], 0.21-0.36) in the fixed-effect model compared with observation only. Three of the 6 included studies showed that the specific death rate related to regional recurrences was lower in the END group than in the observation group in the fixed-effect model (RR = 0.35; 95% CI, 0.19-0.65). The mean metastasis rate of occult cervical lymph node was 30.27% (standard deviation, 9.42%). When the fixed-effect model was applied, 4 of the 6 included studies showed less recurrence in the END group compared with the observation group (RR = 0.53; 95% CI, 0.44-0.64). CONCLUSIONS: END substantially decreases recurrences and deaths related to regional recurrences in early-stage SCC of the oral cavity with clinically N0 neck, especially SCC of the oral tongue and floor of the mouth, which is necessary for such patients.


Asunto(s)
Carcinoma de Células Escamosas , Neoplasias de la Boca , Carcinoma de Células Escamosas/cirugía , China , Humanos , Neoplasias de la Boca/cirugía , Disección del Cuello , Recurrencia Local de Neoplasia , Estadificación de Neoplasias , Estudios Prospectivos , Estudios Retrospectivos , Resultado del Tratamiento
3.
Endocrine ; 2024 Aug 19.
Artículo en Inglés | MEDLINE | ID: mdl-39158800

RESUMEN

PURPOSE: To assess the prevalence of osteosarcopenia (OS) in elderly patients with type 2 diabetes mellitus (T2DM) and explore the related risk factors for developing this condition. METHODS: This cross-sectional study enrolled hospitalized T2DM patients aged 60 years and older. Patients underwent assessments of total hip bone mineral density (BMD), grip strength, the Short Physical Performance Battery (SPPB), and body composition. Based on the 2019 Asian Working Group for Sarcopenia (AWGS) criteria, appendicular skeletal muscle mass (ASM), grip strength, and SPPB were measured to diagnose sarcopenia. BMD and T values of the lumbar spine and hip were measured using dual-energy X-ray absorptiometry (DXA). Osteosarcopenia was defined when both sarcopenia and osteoporosis criteria were met. Statistical analysis included binary logistic regression to identify significant risk factors. RESULTS: A total of 254 hospitalized T2DM patients (80 males and 174 females) were included. They were divided into T2DM-OS (n = 58) and T2DM-NOS (n = 196) groups based on the presence of osteosarcopenia. The average ages were 72.724 ± 6.463 and 69.265 ± 6.035 years, respectively. The prevalence of osteosarcopenia in T2DM patients was 22.8%, with 20.7% (12 males) and 79.3% (46 females) in the T2DM-OS group. After adjusting for confounding factors, it was found that male gender (OR: 5.738, 95% CI: 1.602-20.551, P = 0.007), fasting plasma glucose (OR: 0.904, 95% CI: 0.821-0.995, P = 0.038), and ASMI (OR: 0.049, 95% CI: 0.013-0.184, P < 0.001) were major influencing factors for the development of osteosarcopenia in elderly T2DM patients. CONCLUSIONS: The prevalence of T2DM-OS is relatively high, with male gender, low fasting plasma glucose, and low ASMI identified as risk factors.

4.
ACS Appl Bio Mater ; 2024 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-39350400

RESUMEN

Bacterial resistance to antibiotics can negatively affect the treatment of infected skin wounds. The combination of synergistic antibacterial therapies with photodynamic, photothermal, and chemodynamic therapies has been recognized as one of the most promising approaches. In this study, we have developed MSN@Ce6@MnO2-CS/Ag (MCMA) nanoparticles to serve as powerful antibacterial agents when exposed to both 660 nm visible light and 808 nm near-infrared (NIR) light. Through dual-light irradiation, MCMA can induce hyperthermia and generate reactive oxygen species (ROS), leading to a remarkable enhancement in photothermal antibacterial effects and accelerating wound healing. It has a peroxidase-like catalytic activity and promotes the generation of hydroxyl radicals (·OH) by catalyzing the decomposition of H2O2. In vitro antibacterial experiments demonstrated the excellent antibacterial activity of MCMA. The antibacterial efficacy of MCMA at a concentration of 250 µg ml-1 was found to be 99.6 and 100% toward Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli, respectively, under irradiation with an 808 and 660 nm laser. The results of the animal experiments demonstrated that MCMA can effectively accelerate wound healing through wound ulceration inhabitation. These findings substantiate the assertion that synthetic MCMA represents an efficacious strategy for bacterial inhibition and wound healing.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA